No abstract available.
Female ; Humans ; Osteoporosis, Postmenopausal*

No abstract available.
Diagnosis* ; Female ; Humans ; Osteoporosis, Postmenopausal*

Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the results of those studies and describe the current status of romosozumab as a potential therapy for osteoporosis.
Female ; Humans ; Osteoblasts ; Osteogenesis ; Osteoporosis ; Osteoporosis, Postmenopausal

Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long term bisphosphonate. Pathogenic mechanisms of AFF and BRONJ are not fully identified and not identical. We report a case of BRONJ followed by AFF and its nonunion in a 67-year-old woman patient receiving an oral bisphosphonate during 7 years for the treatment of osteoporosis.
Aged ; Female ; Femoral Fractures* ; Humans ; Jaw* ; Osteonecrosis* ; Osteoporosis* ; Osteoporosis, Postmenopausal

Stress fractures occur when the loads applied to a bone exceed the mechanical resistance and fall into two groups. Fatigue fractures, in which abnormal mechanical stress is applied to a normal bone, and insufficiency fractures, in which fracture occurs when stress of normal activity is applied to a bone that has decreased elastic resistance. Femoral shaft insufficiency fractures are reported rarely in patients with postmenopausal osteoporosis. We report a case of repetitive insufficiency fractures of the femoral shaft in 70 year-old female with marked osteoporosis.
Female ; Fractures, Stress ; Humans ; Osteoporosis ; Osteoporosis, Postmenopausal ; Stress, Mechanical

OBJECTIVE: This study is to examine the physical function, psychological well-being, and subjective symptom of postmenopausal osteoporotic women. METHODS: Data used for this study was collected from 397 women who had experienced one years or longer menopause and visited a hospital in Seoul, Korea during the period from May to December 2005. RESULTS: The level of physical function of the fracture osteoporosis group was significantly lower than the other three groups. The psychological well-being of the fracture osteoporosis group was significantly lower than the other three groups. Subjective symptom of the fracture osteoporosis group was significantly higher than the other three groups. The level of physical function was positively correlated with psychological well-being and negatively with subjective symptom. Psychological well-being was also negatively correlated with the level of subjective symptom. Based on the results, it is recommended that the prevention of vertebral fracture in osteoporotic woman is important, and nursing intervention is necessary for the physical function, psychological well-being, and subjective symptom care.
Female ; Humans ; Korea ; Menopause ; Nursing ; Osteoporosis ; Osteoporosis, Postmenopausal ; Seoul

OBJECTIVETo explore the effect of embedding thread at Shenshu (BL 23) on clinical pain of postmenopausal osteoporosis.

METHODSFifty-six cases were randomly divided into an embedding thread group, an embedding thread plus Leli group and a Leli group. The pain of the patient before treatment, 3 months and 6 months after treatment were assessed.

RESULTSThere was significant difference before and after treatment in the score of pain in both the embedding thread group and the embedding thread plus Leli group (P < 0.001), with no significant difference between the two groups (P > 0.05); there was no significant difference before and after treatment in the score of pain in the Leli group (P > 0.05), but with significant differences as compared with other two groups (both P < 0.001).

CONCLUSIONEmbedding thread at Shenshu (BL 23) has very obvious therapeutic effect on clinical pain of postmenopausal osteoporosis, and oral administration of Leli capsule has no significantly therapeutic effect on clinical pain of postmenopausal osteoporosis.

Advocacy for the use of calcium supplements arose at a time when there were no other effective interventions for the prevention of osteoporosis. Their promotion was based on the belief that increasing calcium intake would increase bone formation. Our current understandings of the biology of bone suggest that this does not occur, though calcium does act as a weak antiresorptive. Thus, it slows postmenopausal bone loss but, despite this, recent meta-analyses suggest no significant prevention of fractures. In sum, there is little substantive evidence of benefit to bone health from the use of calcium supplements. Against this needs to be balanced the likelihood that calcium supplement use increases cardiovascular events, kidney stones, gastrointestinal symptoms, and admissions to hospital with acute gastrointestinal problems. Thus, the balance of risk and benefit seems to be consistently negative. As a result, current recommendations are to obtain calcium from the diet in preference to supplements. Dietary calcium intake has not been associated with the adverse effects associated with supplements, probably because calcium is provided in smaller boluses, which are absorbed more slowly since they come together with quantities of protein and fat, resulting in a slower gastric transit time. These findings suggest that calcium supplements have little role to play in the modern therapeutics of osteoporosis, which is based around the targeting of safe and effective anti-resorptive drugs to individuals demonstrated to be at increased risk of future fractures.
Biology ; Calcium* ; Calcium, Dietary ; Diet ; Female ; Humans ; Kidney Calculi ; Myocardial Infarction ; Osteogenesis ; Osteoporosis* ; Osteoporosis, Postmenopausal

PURPOSE: This study was conducted to compare the radiomorphometric indices of the mandible on panoramic radiographs among three groups of normal, osteopenia and osteoporosis and to determine whether panoramic indices have validity in predicting osteoporotic risk. MATERIALS AND METHODS: Ninty-four postmenupausal women aged 42-72 years (mean 62+/-7.5) were examined using dual energy X-ray absorptionmetry (DEXA) of the lumbar and classified into three groups by WHO classification. Panoramic mandibular index (PMI), mandibular cortical thickness (Mental index (MI), Antegonial index (AI), Gonial index (GI) ) and the mandibular cortical index (MCI) were measured bilaterally on panoramic radiographs and analyzed. RESULTS: There were signigicant differences among normal, osteopenic and osteoporoti groups in PMI (I), PMI (S), MI, AI, GI and MCI. The sensitivities of the MCI (93%) and the combination index of MCI and MI (90%) in diagnosing osteopenic/osteoporotic cases were high. CONCLUSION: The widths and shapes of the mandibular cortical bone on panoramic radiography may highly reflect the systemic osteopenic/osteoporotic conditions of the patients.
Bone Diseases, Metabolic ; Classification ; Female ; Humans ; Mandible* ; Osteoporosis ; Osteoporosis, Postmenopausal ; Radiography, Panoramic

STUDY DESIGN: Retrospective case series. PURPOSE: The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF) in women with postmenopausal osteoporosis. OVERVIEW OF LITERATURE: Clinical data support the efficacy of parathyroid hormone (PTH) for lumbar PLF. However, the use of PTH is limited to 2 years. METHODS: We treated 19 women diagnosed with osteoporosis and degenerative spondylolisthesis with teriparatide (20 µg daily subcutaneously). All patients underwent one-level instrumented PLF. Teriparatide was used during 2 months prior to surgery and more than 8 months after surgery. After discontinuing teriparatide treatment, all patients used bisphosphonate (17.5 mg risedronate weekly, oral administration). Area of the fusion mass across the transverse processes at one segment was determined on an anteroposterior radiograph at 1, 2, and 3 years after surgery. RESULTS: We followed 19 patients for 3 years. The average duration of teriparatide treatment was 11.5 months. The bone union rate was 95%. The average area of the bone fusion mass was not significantly different between the right and left sides at 1, 2, or 3 years after surgery (p>0.05). CONCLUSIONS: This study showed that replacing teriparatide treatment with bisphosphonate maintained the bone fusion mass volume after PLF in women with postmenopausal osteoporosis.
Female ; Humans ; Osteoporosis ; Osteoporosis, Postmenopausal* ; Parathyroid Hormone ; Retrospective Studies ; Risedronate Sodium ; Spine ; Spondylolisthesis ; Teriparatide*